WO2001030331A3 - Compositions therapeutiques comprenant des inhibiteurs de la proteine kinase c - Google Patents
Compositions therapeutiques comprenant des inhibiteurs de la proteine kinase c Download PDFInfo
- Publication number
- WO2001030331A3 WO2001030331A3 PCT/US2000/026254 US0026254W WO0130331A3 WO 2001030331 A3 WO2001030331 A3 WO 2001030331A3 US 0026254 W US0026254 W US 0026254W WO 0130331 A3 WO0130331 A3 WO 0130331A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- inhibitors
- protein kinase
- therapeutic compositions
- compositions including
- including protein
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU11892/01A AU1189201A (en) | 1999-10-22 | 2000-10-13 | Therapeutic compositions including protein kinase c inhibitors |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16112999P | 1999-10-22 | 1999-10-22 | |
US60/161,129 | 1999-10-22 | ||
US17751000P | 2000-01-21 | 2000-01-21 | |
US60/177,510 | 2000-01-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001030331A2 WO2001030331A2 (fr) | 2001-05-03 |
WO2001030331A3 true WO2001030331A3 (fr) | 2002-01-24 |
Family
ID=26857534
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/026254 WO2001030331A2 (fr) | 1999-10-22 | 2000-10-13 | Compositions therapeutiques comprenant des inhibiteurs de la proteine kinase c |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU1189201A (fr) |
WO (1) | WO2001030331A2 (fr) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001271261A1 (en) * | 2000-06-29 | 2002-01-14 | Eli Lilly And Company | Therapeutic treatment of cancer with a protein kinase c inhibitor |
WO2002002094A2 (fr) * | 2000-06-29 | 2002-01-10 | Eli Lilly And Company | Utilisation d'un inhibiteur de la proteine kinase c pour renforcer l'efficacite clinique d'agents chimiotherapeutiques antineoplasiques et celle de la radiotherapie |
CA2393720C (fr) * | 2002-07-12 | 2010-09-14 | Eli Lilly And Company | Monochlorhydrate de 3-(1-methyl-1h-indol-3-yl)-4-[[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole-2,5-dione cristallin |
GB0303319D0 (en) | 2003-02-13 | 2003-03-19 | Novartis Ag | Organic compounds |
WO2005000316A1 (fr) * | 2003-06-25 | 2005-01-06 | Cardiovascular Institute, Ltd. | Preparation a usage externe permettant d'ameliorer la fonction coitale |
DE602004014965D1 (de) * | 2003-10-24 | 2008-08-21 | Lilly Co Eli | Bisindolylmaleimid zur behandlung von prostatakrebs und akt-vermittelten erkrankungen |
US20080096923A1 (en) * | 2004-07-23 | 2008-04-24 | Aniz Girach | Methods For Diagnosing And Treating Diabetic Microvascular Complications |
EP1621201A1 (fr) * | 2004-07-28 | 2006-02-01 | NeuroCode AG | Hesperidin pour la prophylaxe et le traitement de maladies du système nerveux central, en particulier la maladie d'Alzheimer et de Parkinson, pour thérapie après accident ischémique cérébral et de la douleur chronique. |
EP1721613B1 (fr) * | 2005-05-13 | 2007-11-28 | Mewicon med. wiss. Beratung GmbH | Hespéridine pour le traitement de l'épilepsie |
US8785648B1 (en) | 2010-08-10 | 2014-07-22 | The Regents Of The University Of California | PKC-epsilon inhibitors |
AU2013232069B2 (en) | 2012-03-16 | 2017-07-13 | Vitae Pharmaceuticals, Inc. | Liver X receptor modulators |
PL2825541T3 (pl) | 2012-03-16 | 2016-12-30 | Modulatory receptora x wątroby | |
EP3180003B1 (fr) | 2014-07-01 | 2022-01-12 | The Regents of the University of California | Inhibiteurs de pkc-epsilon |
RU2742030C1 (ru) * | 2020-06-11 | 2021-02-01 | Общество с ограниченной ответственностью "ЦитоНИР" (ООО "ЦитоНИР") | Конъюгат гесперидина и способ его получения |
-
2000
- 2000-10-13 WO PCT/US2000/026254 patent/WO2001030331A2/fr active Application Filing
- 2000-10-13 AU AU11892/01A patent/AU1189201A/en not_active Abandoned
Non-Patent Citations (2)
Title |
---|
K.HEHENBERGER, A.HANSSON: "High glucose-induced growth factor resistance in human fibroblasts can be reversed by antioxidants and protein kinase C-inhibitors", CELL BIOCHEMISTRY AND FUNCTION, vol. 15, no. 3, 1997, pages 197 - 201, XP001010004 * |
S.E.BURSELL, G.L.KING: "Can protein kinase C inhibition", DIABETES RESEARCH CLINICAL PRACTICE, vol. 45, no. 2-3, 1999, pages 169 - 182, XP001010001 * |
Also Published As
Publication number | Publication date |
---|---|
AU1189201A (en) | 2001-05-08 |
WO2001030331A2 (fr) | 2001-05-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001019829A3 (fr) | Pyrazolopyrimidines en tant qu'agents therapeutiques | |
WO2003000695A8 (fr) | Pyrrolopyrimidines utilisees en tant qu'inhibiteurs des proteines kinases | |
RS56252B1 (sr) | Jednodnevne formulacije oksikodona | |
WO2001030331A3 (fr) | Compositions therapeutiques comprenant des inhibiteurs de la proteine kinase c | |
AU2001263229A1 (en) | Compositions and methods for administration of pharmacologically active compounds | |
WO2005005414A3 (fr) | Derives de pyrazolyl-indole actifs en tant qu'inhibiteurs de kinase, procede de preparation correspondant et compositions pharmaceutiques les contenant | |
MY129350A (en) | Aripiprazole oral solution | |
CA2363990A1 (fr) | Utilisation de glycyrrhizine pour traiter une mastite | |
AU7031500A (en) | Therapeutic quinazoline compounds | |
CA2426703A1 (fr) | Agents therapeutiques et procede d'utilisation de ces derniers pour modules l'angiogenese | |
IN2005KO00312A (fr) | ||
HK1080459A1 (en) | Novel pyrimidineamide derivatives and the use thereof | |
AU7079700A (en) | Improved stable formulations of ace inhibitors, and methods for preparation thereof | |
AU3850600A (en) | Dalda analogs and their use | |
WO2005014572A8 (fr) | Derives de pyrimidylpyrrole pouvant etre utilises comme inhibiteurs de kinases | |
WO2000045800A3 (fr) | Effets immunosuppresseurs des derives de pteridine | |
WO2002007721A3 (fr) | Methode | |
EP1886691A3 (fr) | Formulation pharmaceutique comprenant un inhibiteur de la thrombine à faible masse moléculaire et son précurseur | |
WO2003005967A3 (fr) | Formulation a liberation double comportant un ester ethylique de levodopa et un inhibiteur de decarboxylase dans une couche a liberation instantanee avec un ester ethylique de levodopa et un inhibiteur de decarboxylase dans un noyau a liberation controlee | |
WO2002102743A3 (fr) | Aminoalkylesters d'acide diphenylalcoxy-acetique n et alpha-substitues deuterises et medicaments contenant lesdits composes | |
WO2001081316A3 (fr) | Inhibiteurs de phenyle farnesyltransferase substitues | |
WO2000001415A3 (fr) | Utilisation d'inhibiteurs de la proteine kinase c epsilon dans le traitement de la douleur | |
JP2003522768A5 (fr) | ||
AU7270798A (en) | Antithrombotic agents | |
WO2003051838A3 (fr) | Inhibiteurs de la proteine kinase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |